To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension.
Prospective, randomized, crossover study
Twenty-two patients pretreated with a prostaglandin analog at baseline were randomly assigned at a 1:1 ratio to either LCFC or LTFC treatment. The patients received the assigned study drug in both eyes daily in the evening (20:00). Each treatment group crossed over after a 2-month treatment period. The 24-h curves of intraocular pressure (IOP), pulse rate, and blood pressure were evaluated. Safety was also assessed.
The changes in mean daytime IOP from baseline at the end of the 2-month treatment period in the LCFC and LTFC groups were – 0.93 and – 1.15 mmHg, respectively. The changes in peak IOP in the 2 groups were – 0.91 and – 0.68 mmHg, respectively. The nighttime pulse rate in the LCFC group increased; that in the LTFC group was lower at all time points. The changes in pulse rate from baseline at 22:00, 2:00, 4:00, and 6:00 differed statistically between the 2 groups. No differences in changes from baseline in systolic and diastolic blood pressures were found between the groups.
The 24-h IOP curve of patients in the LCFC group was similar to that of the LTFC group, but on the basis of the pulse rate findings, the effect of LCFC on the cardiovascular system over 24 h was less than that of LTFC.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Quigley HA. Glaucoma Lancet. 2011;377:1367–77.
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901–11.
Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary open-angle glaucoma preferred practice pattern(®) Guidelines. Ophthalmology. 2016;123:41–111.
Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26–33.
Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–8.
Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016;93:668–74.
Tsumura T, Kashiwagi K, Suzuki Y, Yoshikawa K, Suzumura H, Maeda T, et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39:375–83.
Sakamoto M, Kitamura K, Kashiwagi K. Changes in glaucoma medication during the past eight years and future directions in Japan based on an Insurance Medical Claim Database. J Ophthalmol. 2017;2017:7642049.
Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging. 2007;24:509–28.
Tripathy K, Geetha R. Latanoprost. In: StatPearls [Internet]. StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540978/.
Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol. 1986;102:606–11.
Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group Am J Ophthalmol. 1997;123:465–77.
Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5 % in patients with increased intraocular pressure; Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol. 1997;124:498–505.
Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs. 2007;12:313–27.
Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67:237–45.
Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers: a randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand. 2001;79:567–71.
Luu KT, Raber SR, Nickens DJ, Vicini P. A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther. 2010;87:421–5.
Ministry of Health, Labour and Welfare. Clinical Trials Act (Act No. 16 of April 14, 2017). https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000163413.pdf.
Yamamoto T, Ikegami T, Ishikawa Y, Kikuchi S. OPC-1085EL 1 & 2 Study Groups. Randomized, controlled, phase 3 trials of carteolol/latanoprost fixed combination in primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2016;171:35–46.
Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221–32.
Soares RR, Razeghinejad MR. Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2018;19:1731–8.
Inoue K, Shiokawa M, Iwasa M, Ishida K, Tomita G. Short-term efficacy and safety of a latanoprost/carteolol fixed combination switched from concomitant therapy to in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2018;27:1175–80.
Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–73.
Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010;54:140–3.
Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian IOP, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One. 2015;10:e0140601.
Martinez-de-la-Casa JM, Garcia-Feijoo J, Saenz-Frances F, Vizzeri G, Fernandez-Vidal A, Mendez-Hernandez C, et al. Comparison of rebound tonometer and Goldmann handheld applanation tonometer in congenital glaucoma. J Glaucoma. 2009;18:49–52.
Arribas-Pardo P, Mendez-Hernández C, Valls-Ferran I, Puertas-Bordallo D. Icare-Pro rebound tonometer versus hand-held applanation tonometer for pediatric screening. J Pediatr Ophthalmol Strabismus. 2018;55:382–6.
Mendez-Hernandez C, Arribas-Pardo P, Jean RS, Garcia-Feljoo J. Influence of axial length on intraocular pressure measurement with three tonometers in childhood glaucoma. J Pediatr Ophthalmol Strabismus. 2020;57:27–32.
Stewart WC, Castelli WP. Systemic side effects of topical beta-adrenergic blockers. Clin Cardiol. 1996;19:691–7.
Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15:1549–61.
Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301–9.
Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint JM, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556–63.
Chrisp P, Sorkin EM. Ocular carteolol: a review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1992;2:58–77.
Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett. 2001;122:1–8.
Höh H, Nastainczyk W. Beta blockers and corneal sensitivity. Article in German Fortschr Ophthalmol. 1991;88:515–21.
Inoue K, Okugawa K, Kato S, Inoue Y, Tomita G, Oshika T, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12:480–5.
This study was funded by Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. We thank Dr Tetsuji Asao (SunFlare Co., Ltd., Tokyo, Japan) for medical writing services. We also appreciate Mr Hidetoshi Uenaka for statistical analysis services, Mr Taishi Okamoto for EDC system development, and Ms Fumiko Okamoto—all of intellim Corporation Co., Ltd., Tokyo, Japan—for statistical analysis programing. The services provided by all of the aforementioned individuals were funded by Otsuka Pharmaceutical Co., Ltd.
Conflicts of interest
Y. Saito, Grant (Otsuka); J. Kizaki, Grant (Otsuka); Y. Wada, Grant (Otsuka); Y. Shibasaki, Employee (Otsuka); N. Kishimoto, Employee (Otsuka); M. Aihara, Grant (Otsuka).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding Author: Yuta Saito
Below is the link to the electronic supplementary material.
About this article
Cite this article
Saito, Y., Kizaki, J., Wada, Y. et al. Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. Jpn J Ophthalmol 65, 598–607 (2021). https://doi.org/10.1007/s10384-021-00856-2
- Cardiovascular effect
- Fixed combination
- Primary open-angle glaucoma